BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, February 9, 2026
Home » Authors » Mark McCarty

Articles by Mark McCarty

Washington roundup: Integrity agreement training mandates called burdensome

Oct. 11, 2012
By Mark McCarty

Washington roundup: IsoAid warned over validation procedures, sterilization issues

Oct. 10, 2012
By Mark McCarty

Washington roundup: Aetna, Anthem deem left atrial hemo monitoring experimental

Oct. 9, 2012
By Mark McCarty

Washington roundup: House Republicans urge a halt to Medicare EHR incentives

Oct. 8, 2012
By Mark McCarty

Persistence is futile: EHR interoperability

Oct. 7, 2012
By Mark McCarty
Trekkies and non-Trekkies alike will recognize the expression “resistance is futile” as a favored saying among the drones of the Borg collective of Star Trek fame. Obviously I’m paraphrasing with the title of this essay, but let’s ask ourselves a question: Is it a big deal that the Department of Health and Human Services still does not have an agreed-upon standard for electronic health record (EHR) interoperability? HHS has been yakking about this since 2005, when Mike Leavitt ran the department. Now we have Kathleen Sebelius and still no...
Read More

Prometheus expected to shift balance of power to big firms

Oct. 5, 2012
By Mark McCarty
BOSTON – The last day of AdvaMed 2012 included a discussion of the case of Prometheus v. Mayo that left observers with little reason for optimism unless the observer was employed by a large commercial entity with a good budget for legal consultation. Otherwise, holders and would-be holders of intellectual property might find the outcome of Prometheus leaves them ill equipped to manage patents and patent portfolios in a way that steers around some of the issues that arose in the case, which is expected to not only reshape the contours of the patent landscape going forward, but could eviscerate a number of existing patents as well.
Read More

Industry wants more detail for unsolicited off-label inquiries

Oct. 4, 2012
By Mark McCarty
BOSTON — The second day of AdvaMed 2012, hosted by the Advanced Medical Technology Association (AdvaMed; Washington), included a session dealing with the recent guidance for responding to unsolicited inquiries into off-label indications, and many in attendance may have hoped for a promise from FDA that it would fill in the blanks in the December 2011 guidance on this subject.
Read More

Trautman: IMDRF following other efforts on single audits

Oct. 4, 2012
By Mark McCarty

AQC program sees savings, but new tech is a concern

Oct. 3, 2012
By Mark McCarty
BOSTON — Reform of healthcare delivery and payment are jointly the signature healthcare experiment in this first part of the 21st Century, and a paper in the August edition of Health Affairs demonstrates that at least one approach to bundled payment can suppress the rate of healthcare inflation without inflicting damage on quality of care. However, one member of a trade association said the latest research does little to allay fears that new technology will suffer under cost containment efforts.
Read More

AdvaMed to push for device tax repeal in fiscal cliff legislation

Oct. 2, 2012
By Mark McCarty
BOSTON — The Advanced Medical Technology Association (AdvaMed; Washington) kicked off its annual meeting with a policy briefing, highlighting some of its imperatives for 2012, with issues of taxation dominating the agenda. Repeal of the device tax is obviously still high on the association's agenda, and Steve Ubl, president/CEO of AdvaMed, said the association's preference is that a repeal be packaged with legislation dealing with the oncoming fiscal cliff composed of other tax issues.
Read More
Previous 1 2 … 420 421 422 423 424 425 426 427 428 … 579 580 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 6, 2025.
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Liver anatomy illustration

    KLF15 shows potential as marker, target for cholangiocarcinoma

    BioWorld Science
    Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 3, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing